Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIBiomarker/Laboratory analysis, Supportive care, TreatmentActive60 and overNCI, OtherE1411
ECOG-E1411, NCI-2011-02980, CDR0000707057, NCT01415752

Trial Description

Summary

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as bendamustine hydrochloride, also work in different ways to kill cancer cells or stop them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of mantle cell lymphoma by blocking blood flow to the cancer. It is not yet known whether giving rituximab together with bendamustine and bortezomib is more effective than rituximab and bendamustine, followed by rituximab alone or with lenalidomide in treating mantle cell lymphoma.

PURPOSE: This randomized phase II trial studies rituximab, bortezomib, bendamustine, and lenalidomide in treating previously untreated older patients with mantle cell lymphoma.

Further Study Information

OBJECTIVES:

Primary

  • To determine whether the addition of bortezomib (RBV) to an induction regimen of rituximab-bendamustine hydrochloride (RB) improves progression-free survival (PFS) compared to RB alone in patients ≥ 60 years of age with previously untreated mantle cell lymphoma.
  • To determine whether the addition of lenalidomide to a consolidation regimen of rituximab following an induction regimen of RB or RBV improves PFS compared to consolidation rituximab alone in this patient population.

Secondary

  • To determine whether the addition of bortezomib to induction therapy improves the positron emission tomography (PET)-documented complete response (CR) rate compared to RB alone.
  • To determine the objective response rate (ORR) for RB and RBV.
  • Among patients who do not have PET-documented CR at the end of induction, to determine whether the addition of lenalidomide to consolidation therapy improves CR and ORR compared with rituximab alone.
  • To determine overall survival (OS) in the treatment arms.
  • To determine safety, with attention to the addition of bortezomib in the induction regimen and lenalidomide-rituximab (LR) as consolidation therapy.
  • To collect paraffin-embedded tissue for creation of tissue microarray.
  • To collect and bank serum and blood mononuclear cells for future studies.
  • To collect formalin-fixed paraffin-embedded (FFPE) tissue to analyze potential prognostic factors (Ki-67 proliferation index by immunohistochemistry and correlation with proposed 5-gene set of proliferation markers analyzed by RNA PCR; SOX 11 expression by immunohistochemistry; and Micro-RNA levels by microarray).
  • Using patient-reported outcomes data, to determine the extent and severity of neuropathy associated with the addition of bortezomib to induction treatment.
  • Using patient-reported outcomes data, to determine the extent and severity of fatigue associated with the addition of lenalidomide to consolidation treatment.
  • To evaluate the effects of the addition of bortezomib and lenalidomide on patient-reported health-related quality of life.
  • To evaluate the effects of bortezomib-related neuropathy on patient-reported health-related quality of life.
  • To evaluate the response of lymphoma-specific symptoms to treatment.
  • Using longitudinal patient-reported outcomes data, to describe the trajectory of lymphoma symptoms, neuropathy, fatigue, and overall health-related quality of life prior to, during, and following treatment among older adults with MCL.

Tertiary

  • To assess the proportion of patients up and down staging when fludeoxyglucose F 18- (FDG) PET/CT is added to standard Ann Arbor staging.
  • To assess the ability of pre-treatment FDG-PET/CT (SUVmax) to predict response rate and PFS.
  • Among patients with interim (post-cycle 3) FDG-PET/CT imaging, to assess the correlation of interim FDG-PET/CT imaging with response rate and PFS both during induction and consolidation therapy.
  • To assess standard FDG-PET/CT metrics including SUVmax, tumor metabolic burden, total tumor burden, and association with pathology features (blastoid variant vs other, and Ki67) in the setting of MCL.
  • To assess differences in overall and CR rates when using Deauville vs International Harmonization Project FDG-PET/CT interpretation criteria.
  • To determine whether there is a correlation between FDG-PET/CT response and residual disease assessment by molecular and/or flow cytometric techniques.
  • To determine whether the number of malignant cells in circulation predict the number of cells in marrow.
  • To determine whether the number of malignant cells in circulation/in marrow at the end of induction correlate with CR and 2-year PFS.
  • To determine whether there is a higher rate of minimal residual disease (MRD) negativity among patients randomized to RBV as compared with RB, and among patients treated with LR maintenance compared with rituximab.
  • To compare the two methods of MRD detection - molecular techniques and flow cytometry - as prognostic markers for outcome.

OUTLINE: This is a multicenter study. Patients are stratified according to mantle cell lymphoma International Prognostic Index risk score (low vs intermediate vs high). Patients are randomized to 1 of 4 treatment arms.

  • Arm A: Patients receive induction therapy comprising rituximab IV on day 1 and bendamustine hydrochloride IV over 60 minutes on days 1-2. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
  • Arm E: Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
  • Arm B: Patients receive induction therapy comprising bortezomib IV or subcutaneously (SC) on days 1, 4, 8, and 11 and rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
  • Arm F: Patients receive consolidation therapy comprising rituximab IV on day 1. Courses repeat every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
  • Arm C: Patients receive induction therapy comprising rituximab and bendamustine hydrochloride as patients in arm A. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
  • Arm G: Patients receive consolidation therapy comprising lenalidomide orally (PO) daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.
  • Arm D: Patients receive bortezomib, rituximab, and bendamustine hydrochloride as patients in arm B. Treatment repeats every 4 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.
  • Arm H: Patients receive consolidation therapy comprising lenalidomide PO daily on days 1-21 every 4 weeks and rituximab IV every 8 weeks for 2 years in the absence of disease progression or unacceptable toxicity.

Patients may undergo blood and bone marrow sample collection at baseline and during treatment for correlative studies.

Patients complete the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym), the FACT/GOG-Neurotoxicity scale (FACT/GOG-Ntx), FACT-Fatigue, and FACT-General questionnaires at baseline and periodically during study and follow up.

After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 3 years, and then annually for 10 years.

Eligibility Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed untreated mantle cell lymphoma (MCL), with documented cyclin D1 by immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescence in situ hybridization (FISH)
  • Patients must have at least one objective measurable disease parameter
  • Abnormal PET scans will not constitute evaluable disease, unless verified by CT scan or other appropriate imaging
  • Measurable disease in the liver is required if the liver is the only site of lymphoma
  • Patient must have no CNS involvement

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-2
  • ANC ≥ 1,500/mcL (1.5 x 10^9/L)*
  • Platelets ≥ 100,000/mcL (100 x 10^9/L)* NOTE: *Unless due to marrow involvement.
  • AST/ALT ≤ 2 times upper limit of normal (ULN)
  • Bilirubin ≤ 2 times ULN
  • Calculated creatinine clearance by Cockroft-Gault formula ≥ 30 mL/min
  • Women (sexually mature female) must not be pregnant or breast-feeding
  • Negative pregnancy test
  • Women of childbearing potential and sexually active males use an accepted and effective method of contraception
  • Men must agree to use a latex condom during sexual contact with a female of child-bearing potential, even if they have had a successful vasectomy
  • All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure
  • No evidence of prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical carcinoma, or any surgically or radiation-cured malignancy continuously disease free for ≥ 5 years so as not to interfere with interpretation of radiographic response
  • Patient agrees that if randomized to Arms C or D, and proceed onto Arms G or H, they must register into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®
  • Patients must have no medical contra-indications to, and be willing to take, deep vein thrombosis (DVT) prophylaxis as all patients registering to the lenalidomide/rituximab Arms G and H will be required to have DVT prophylaxis
  • Patients randomized to Arms G or H who have a history of a thrombotic vascular event will be required to have therapeutic doses of low-molecular weight heparin or warfarin to maintain an INR between 2.0 - 3.0
  • Patients on Arms G and H without a history of a thromboembolic event are required to take a daily aspirin (81 mg or 325 mg) for DVT prophylaxis
  • Patients who are unable to tolerate aspirin should receive low molecular weight heparin therapy or warfarin treatment
  • Women must agree to abstain from donating blood during study participation and for at least 28 days after discontinuation from protocol treatment
  • Males must agree to abstain from donating blood, semen, or sperm during study participation and for at least 28 days after discontinuation from protocol treatment
  • HIV-positive patients are not excluded but, to enroll, must meet all of the below criteria:
  • HIV is sensitive to antiretroviral therapy
  • Must be willing to take effective antiretroviral therapy, if indicated
  • No history of CD4 prior to or at the time of lymphoma diagnosis < 300 cells/mm³
  • No history of AIDS-defining conditions
  • If on antiretroviral therapy, must not be taking zidovudine or stavudine
  • Must be willing to take prophylaxis for Pneumocystis jiroveci pneumonia (PCP) during therapy and until at least 2 months following the completion of therapy or until the CD4 cells recover to over 250 cells/mm³, whichever occurs later
  • Patients must not have grade 2 or greater peripheral neuropathy
  • Patients must not have NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia
  • Patients must not have hypersensitivity to bortezomib, boron, or mannitol
  • Patients must not have a serious medical or psychiatric illness likely to interfere with study participation

PRIOR CONCURRENT THERAPY:

  • No prior therapy for MCL, except < 1 week of steroid therapy for symptom control
  • HIV-positive patients are not excluded, but to enroll, must meet all of the below criteria:
  • Must be willing to take effective antiretroviral therapy if indicated
  • If on antiretroviral therapy, must not be taking zidovudine or stavudine
  • Patients must not be participating in any other clinical trial or taking any other experimental medications within 14 days prior to registration

Trial Contact Information

Trial Lead Organizations/Sponsors

Eastern Cooperative Oncology Group

  • National Cancer Institute
Mitchell Reed Smith, Principal Investigator

Trial Sites

U.S.A.

Alaska
Anchorage

Alaska Breast Care and Surgery LLC

Alison K Conlin
Ph: 503-215-6412

Alaska Women's Cancer Care

Alison K Conlin
Ph: 503-215-6412

Anchorage Oncology Centre

Alison K Conlin
Ph: 503-215-6412

Katmai Oncology Group

Alison K Conlin
Ph: 503-215-6412

Providence Cancer Center

Alison K Conlin
Ph: 503-215-6412

California
Antioch

Kaiser Permanente - Deer Valley

Tatjana Kolevska
Ph: 626-564-3455

Fremont

Kaiser Permanente - Fremont

Tatjana Kolevska
Ph: 626-564-3455

Fresno

Kaiser Permanente Fresno Medical Center

Tatjana Kolevska
Ph: 626-564-3455

Modesto

Kaiser Permanente-Modesto

Tatjana Kolevska
Ph: 626-564-3455

Oakland

Kaiser Permanente-Oakland

Tatjana Kolevska
Ph: 626-564-3455

Redwood City

Kaiser Permanente Medical Center - Redwood City

Tatjana Kolevska
Ph: 626-564-3455

Richmond

Kaiser Permanente Medical Center - Richmond

Tatjana Kolevska
Ph: 626-564-3455

Roseville

Kaiser Permanente Medical Center - Roseville

Tatjana Kolevska
Ph: 626-564-3455

Sacramento

Kaiser Permanente Medical Center - Sacramento

Tatjana Kolevska
Ph: 626-564-3455

South Sacramento Kaiser-Permanente Medical Center

Tatjana Kolevska
Ph: 626-564-3455

San Francisco

Kaiser Permanente Medical Center - San Francisco Geary Campus

Tatjana Kolevska
Ph: 626-564-3455

San Jose

Kaiser Permanente Medical Center - Santa Teresa

Tatjana Kolevska
Ph: 626-564-3455

San Leandro

Kaiser Permanente Medical Center - Hayward

Tatjana Kolevska
Ph: 626-564-3455

San Rafael

Kaiser Foundation Hospital - San Rafael

Tatjana Kolevska
Ph: 626-564-3455

Santa Clara

Kaiser Permanente Medical Center - Santa Clara Homestead Campus

Tatjana Kolevska
Ph: 626-564-3455

Santa Rosa

Kaiser Permanente Medical Center - Santa Rosa

Tatjana Kolevska
Ph: 626-564-3455

South San Francisco

Kaiser Permanente Medical Center - South San Francisco

Tatjana Kolevska
Ph: 626-564-3455

Stockton

Kaiser Permanente Medical Facility - Stockton

Tatjana Kolevska
Ph: 626-564-3455

Vacaville

Kaiser Permanente Medical Center - Vacaville

Tatjana Kolevska
Ph: 626-564-3455

Vallejo

Kaiser Permanente Medical Center - Vallejo

Tatjana Kolevska
Ph: 626-564-3455

Walnut Creek

Kaiser Permanente Medical Center - Walnut Creek

Tatjana Kolevska
Ph: 626-564-3455

Colorado
Aurora

Medical Center of Aurora - South Campus

Keren Sturtz
Ph: 888-785-6789

Rocky Mountain Cancer Centers - Aurora

Keren Sturtz
Ph: 888-785-6789

Boulder

Boulder Community Hospital

Keren Sturtz
Ph: 888-785-6789

Rocky Mountain Cancer Centers-Boulder

Keren Sturtz
Ph: 888-785-6789

Colorado Springs

Penrose Cancer Center at Penrose Hospital

Keren Sturtz
Ph: 888-785-6789

Rocky Mountain Cancer Centers at the Pavilion

Keren Sturtz
Ph: 888-785-6789

Denver

CCOP - Colorado Cancer Research Program

Keren Sturtz
Ph: 888-785-6789

Colorado Blood Cancer Institute

Keren Sturtz
Ph: 888-785-6789

Kaiser Permanente of Colorado

Alexander Menter
Ph: 303-614-1300

Porter Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Presbyterian - St. Luke's Medical Center

Keren Sturtz
Ph: 888-785-6789

Rocky Mountain Cancer Centers - Denver Midtown

Keren Sturtz
Ph: 888-785-6789

Rocky Mountain Cancer Centers-Rose

Keren Sturtz
Ph: 888-785-6789

Rose Medical Center

Keren Sturtz
Ph: 888-785-6789

St. Joseph Hospital

Keren Sturtz
Ph: 888-785-6789

Durango

Mercy Medical Center

Keren Sturtz
Ph: 888-785-6789

Southwest Oncology, PC

Keren Sturtz
Ph: 888-785-6789

Englewood

Comprehensive Cancer Care and Research Institute of Colorado LLC

Keren Sturtz
Ph: 888-785-6789

Swedish Medical Center

Keren Sturtz
Ph: 888-785-6789

Fort Collins

Poudre Valley Hospital

Regina J Brown
Ph: 970-297-6150

Golden

Mountain Blue Cancer Care Center

Keren Sturtz
Ph: 888-785-6789

Greeley

North Colorado Medical Center

Keren Sturtz
Ph: 888-785-6789

Greenwood Village

Breast Cancer Care Consultants

Keren Sturtz
Ph: 888-785-6789

Lafayette

Kaiser Permanente - Lafayette

Alexander Menter
Ph: 303-614-1300

Lakewood

Rocky Mountain Cancer Centers-Lakewood

Keren Sturtz
Ph: 888-785-6789

St. Anthony Central Hospital

Keren Sturtz
Ph: 888-785-6789

Littleton

Littleton Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Rocky Mountain Cancer Centers - Littleton

Keren Sturtz
Ph: 888-785-6789

Lone Tree

Kaiser Permanente-Lone Tree

Alexander Menter
Ph: 303-614-1300

Rocky Mountain Cancer Centers - Lone Tree

Keren Sturtz
Ph: 888-785-6789

Sky Ridge Medical Center

Keren Sturtz
Ph: 888-785-6789

Longmont

Hope Cancer Care Center at Longmont United Hospital

Keren Sturtz
Ph: 888-785-6789

Rocky Mountain Cancer Centers - Longmont

Keren Sturtz
Ph: 888-785-6789

Loveland

McKee Medical Center

Keren Sturtz
Ph: 888-785-6789

Parker

Parker Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Rocky Mountain Cancer Centers - Parker

Keren Sturtz
Ph: 888-785-6789

Pueblo

Rocky Mountain Cancer Centers - Pueblo

Keren Sturtz
Ph: 888-785-6789

St. Mary - Corwin Regional Medical Center

Keren Sturtz
Ph: 888-785-6789

Thornton

Rocky Mountain Cancer Centers - Thornton

Keren Sturtz
Ph: 888-785-6789

Wheat Ridge

Exempla Lutheran Medical Center

Keren Sturtz
Ph: 888-785-6789

Connecticut
Hartford

Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center

Christopher M Reynolds
Ph: 734-712-4673

Delaware
Lewes

Tunnell Cancer Center at Beebe Medical Center

Gregory A. Masters
Ph: 302-733-6227

Newark

Christiana Gynecologic Oncology, LLC

Gregory A. Masters
Ph: 302-733-6227

Delaware Clinical and Laboratory Physicians

Gregory A. Masters
Ph: 302-733-6227

Helen F. Graham Cancer Center at Christiana Hospital

Gregory A. Masters
Ph: 302-733-6227

Gregory A. Masters
Ph: 302-733-6227

Medical Oncology Hematology Consultants, PA at Helen F. Graham Cancer Center

Gregory A. Masters
Ph: 302-733-6227

Regional Hematology/Oncology, PA - Newark

Gregory A. Masters
Ph: 302-733-6227

Rehoboth Beach

Beebe Health Campus

Gregory A. Masters
Ph: 302-733-6227

Seaford

Nanticoke Memorial Hospital

Gregory A. Masters
Ph: 302-733-6227

Wilmington

Christiana Care Health System-Wilmington Hospital

Gregory A. Masters
Ph: 302-733-6227

District of Columbia
Washington

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center

Bruce David Cheson
Ph: 202-444-0381

Florida
Orlando

M.D. Anderson Cancer Center at Orlando

Jose E. Sarriera
Ph: 321-841-7246
Email: CancerClinicalTrials@orlandohealth.com

Hawaii
Aiea

Kapiolani Medical Center at Pali Momi

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Ph: 808-586-2979

Honolulu

Cancer Research Center of Hawaii

Jeffrey L. Berenberg
Ph: 808-586-2979

Kaiser Permanente - Moanalua Medical Center and Clinic

Tatjana Kolevska
Ph: 626-564-3455

Kapiolani Medical Center for Women and Children

Jeffrey L. Berenberg
Ph: 808-586-2979

OnCare Hawaii, Incorporated - Kuakini

Jeffrey L. Berenberg
Ph: 808-586-2979

Jeffrey L. Berenberg
Ph: 808-586-2979

OnCare Hawaii, Incorporated - Lusitana

Jeffrey L. Berenberg
Ph: 808-586-2979

Queen's Cancer Institute at Queen's Medical Center

Jeffrey L. Berenberg
Ph: 808-586-2979

Straub Clinic and Hospital, Incorporated

Jeffrey L. Berenberg
Ph: 808-586-2979

Lihue

Kauai Medical Clinic

Jeffrey L. Berenberg
Ph: 808-586-2979

Idaho
Boise

Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center

Christopher M Reynolds
Ph: 734-712-4673

Coeur D'Alene

Kootenai Medical Center

Benjamin Thomas Marchello
Ph: 800-648-6274

Post Falls

Kootenai Cancer Center - Post Falls

Benjamin Thomas Marchello
Ph: 800-648-6274

Sandpoint

Kootenai Cancer

Benjamin Thomas Marchello
Ph: 800-648-6274

Illinois
Carbondale

Memorial Hospital of Carbondale

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Centralia

Centralia Oncology Clinic

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Chicago

John H. Stroger, Jr. Hospital of Cook County

Luis D Sumoza Benitez
Ph: 312-864-6000

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Jane N. Winter
Ph: 312-695-1301
Email: cancer@northwestern.edu

Danville

Carle on Vermilion

Maria T Grosse-Perdekamp
Ph: 800-446-5532

Decatur

Cancer Care Center of Decatur

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Decatur Memorial Hospital Cancer Care Institute

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Effingham

Carle Physician Group-Effingham

Maria T Grosse-Perdekamp
Ph: 800-446-5532

Crossroads Cancer Center

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Highland Park

Hematology Oncology Associates of Illinois-Highland Park

Jane N. Winter
Ph: 312-695-1301
Email: cancer@northwestern.edu

Kankakee

Provena St. Mary's Regional Cancer Center - Kankakee

Jane N. Winter
Ph: 312-695-1301
Email: cancer@northwestern.edu

Libertyville

North Shore Oncology and Hematology Associates, Limited - Libertyville

Jane N. Winter
Ph: 312-695-1301
Email: cancer@northwestern.edu

Mattoon

Carle Physician Group-Mattoon/Charleston

Maria T Grosse-Perdekamp
Ph: 800-446-5532

Mount Vernon

Good Samaritan Regional Health Center

Jay W Carlson
Ph: 800-821-7532

Niles

Cancer Care and Hematology Specialists of Chicagoland - Niles

Jane N. Winter
Ph: 312-695-1301
Email: cancer@northwestern.edu

Rockford

Advanced Care and Treatment Medical Group, PC

Harvey Eric Einhorn
Ph: 779-696-9400
Email: cancercare@swedishamerican.org

Skokie

Hematology Oncology Associates - Skokie

Jane N. Winter
Ph: 312-695-1301
Email: cancer@northwestern.edu

Springfield

Regional Cancer Center at Memorial Medical Center

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Urbana

Carle Cancer Center at Carle Foundation Hospital

Maria T Grosse-Perdekamp
Ph: 800-446-5532

Maria T Grosse-Perdekamp
Ph: 800-446-5532

Indiana
Michigan City

Saint Anthony Memorial Health Centers

Maria T Grosse-Perdekamp
Ph: 800-446-5532

Woodland Cancer Care Center

Maria T Grosse-Perdekamp
Ph: 800-446-5532

Richmond

Reid Hospital & Health Care Services

Howard M. Gross
Ph: 937-775-1350

Iowa
Ames

McFarland Clinic, PC

Joseph James Merchant
Ph: 515-239-2621

William R. Bliss Cancer Center at Mary Greeley Medical Center

Joseph James Merchant
Ph: 515-239-2621

Boone

McFarland Clinic PC-Boone

Joseph James Merchant
Ph: 515-239-2621

Cedar Rapids

Cedar Rapids Oncology Associates

Deborah W Wilbur
Ph: 319-363-2690

Mercy Regional Cancer Center at Mercy Medical Center

Deborah W Wilbur
Ph: 319-363-2690

Fort Dodge

Trinity Regional Medical Center

Joseph James Merchant
Ph: 515-239-2621

Jefferson

McFarland Clinic PC-Jefferson

Joseph James Merchant
Ph: 515-239-2621

Marshalltown

McFarland Clinic PC-Marshalltown

Joseph James Merchant
Ph: 515-239-2621

Sioux City

Siouxland Hematology-Oncology Associates, LLP

Donald Bruce Wender
Ph: 712-252-0088

Kansas
Lawrence

Lawrence Memorial Hospital

Shaker R. Dakhil
Ph: 316-262-4467

Overland Park

Menorah Medical Center

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Saint Luke's Hospital - South

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Topeka

Cotton-O'Neil Cancer Center

Karissa W Boyd
Ph: 785-270-4963

Wichita

Wesley Medical Center

Shaker R. Dakhil
Ph: 316-262-4467

Kentucky
Crestview Hills

Oncology Hematology Care, Incorporated - Crestview Hills

Howard M. Gross
Ph: 937-775-1350

Louisiana
Baton Rouge

Ochsner Health Center - Bluebonnet

Robert V. Emmons
Ph: 888-562-4763

New Orleans

New Orleans Cancer Institute at Memorial Medical Center

Robert V. Emmons
Ph: 888-562-4763

Ochsner Cancer Institute at Ochsner Clinic Foundation

Robert V. Emmons
Ph: 888-562-4763

Maine
Bangor

CancerCare of Maine at Eastern Maine Medical Center

Thomas Henry Openshaw
Ph: 207-973-4274

Maryland
Baltimore

Alvin and Lois Lapidus Cancer Institute at Sinai Hospital

Roberto F Martinez
Ph: 410-601-6120
Email: pridgely@lifebridgehealth.org

Harry and Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center

Suman B Rao
Ph: 443-777-7364

Silver Spring

Holy Cross Hospital

Frederick D Min
Ph: 310-754-7552

Massachusetts
Boston

Tufts Medical Center Cancer Center

Andrew M Evens
Ph: 617-636-5000
Email: ContactUsCancerCenter@TuftsMedicalCenter.org

Fitchburg

Simonds-Sinon Regional Cancer Center at HealthAlliance Hospital - Burbank Campus

Alan Glen Rosmarin
Ph: 508-856-3216
Email: cancer.research@umassmed.edu

Springfield

Baystate Medical Center

Syed S Ali
Ph: 413-794-3565
Email: tamara.wrenn@baystatehealth.org

Worcester

UMASS Memorial Cancer Center - University Campus

Alan Glen Rosmarin
Ph: 508-856-3216
Email: cancer.research@umassmed.edu

Michigan
Ann Arbor

Saint Joseph Mercy Cancer Center

Christopher M Reynolds
Ph: 734-712-4673

Battle Creek

Battle Creek Health System Cancer Care Center

Gilbert D Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Dearborn

Oakwood Cancer Center at Oakwood Hospital and Medical Center

Christopher M Reynolds
Ph: 734-712-4673

Detroit

Van Elslander Cancer Center at St. John Hospital and Medical Center

Christopher M Reynolds
Ph: 734-712-4673

Wayne State University

Radhakrishnan Ramchandren
Ph: 313-576-9363

Escanaba

Green Bay Oncology, Limited - Escanaba

Brian L Burnette
Ph: 800-432-6049

Farmington Hills

Weisberg Cancer Treatment Center

Radhakrishnan Ramchandren
Ph: 313-576-9363

Flint

Genesys Hurley Cancer Institute

Christopher M Reynolds
Ph: 734-712-4673

Hurley Medical Center

Christopher M Reynolds
Ph: 734-712-4673

Grand Rapids

Butterworth Hospital at Spectrum Health

Gilbert D Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Lacks Cancer Center at Saint Mary's Health Care

Gilbert D Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Iron Mountain

Green Bay Oncology - Iron Mountain

Brian L Burnette
Ph: 800-432-6049

Jackson

Gayle M. Jacob Cancer Center at Allegiance Health

Christopher M Reynolds
Ph: 734-712-4673

Kalamazoo

Borgess Medical Center

Raymond Sterling Lord
Ph: 269-373-7458

Bronson Methodist Hospital

Raymond Sterling Lord
Ph: 269-373-7458

West Michigan Cancer Center

Raymond Sterling Lord
Ph: 269-373-7458

Lansing

Sparrow Regional Cancer Center

Christopher M Reynolds
Ph: 734-712-4673

Livonia

St. Mary Mercy Hospital

Christopher M Reynolds
Ph: 734-712-4673

Muskegon

Mercy General Health Partners

Gilbert D Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Niles

Lakeland Hospital - Niles

Gilbert D Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Pontiac

St. Joseph Mercy Oakland

Christopher M Reynolds
Ph: 734-712-4673

Port Huron

Mercy Regional Cancer Center at Mercy Hospital

Christopher M Reynolds
Ph: 734-712-4673

Reed City

Spectrum Health Reed City Hospital

Gilbert D Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Saginaw

Seton Cancer Institute at Saint Mary's - Saginaw

Christopher M Reynolds
Ph: 734-712-4673

Saint Joseph

Lakeside Cancer Specialists, PLLC

Gilbert D Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

St. Joseph

Lakeland Regional Cancer Care Center - St. Joseph

Gilbert D Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Traverse City

Munson Medical Center

Gilbert D Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Warren

St. John Macomb Hospital

Christopher M Reynolds
Ph: 734-712-4673

Minnesota
Burnsville

Fairview Ridges Hospital

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Coon Rapids

Mercy and Unity Cancer Center at Mercy Hospital

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Duluth

CCOP - Duluth

Bret E Friday
Ph: 888-203-7267

Essentia Health - Duluth Clinic

Bret E Friday
Ph: 888-203-7267

Miller - Dwan Medical Center

Bret E Friday
Ph: 888-203-7267

Edina

Fairview Southdale Hospital

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Fridley

Mercy and Unity Cancer Center at Unity Hospital

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Hutchinson

Hutchinson Area Health Care

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Maplewood

HealthEast Cancer Care at St. John's Hospital

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Minnesota Oncology - Maplewood

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Minneapolis

Health Partners Inc

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Hennepin County Medical Center - Minneapolis

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Virginia Piper Cancer Institute at Abbott - Northwestern Hospital

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Robbinsdale

Humphrey Cancer Center at North Memorial Outpatient Center

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Rochester

Mayo Clinic Cancer Center

David James Inwards
Ph: 507-538-7623

Saint Louis Park

Park Nicollet Cancer Center

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Saint Paul

Regions Hospital Cancer Care Center

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

United Hospital

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Shakopee

St. Francis Cancer Center at St. Francis Medical Center

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Waconia

Ridgeview Medical Center

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Willmar

Willmar Cancer Center at Rice Memorial Hospital

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Woodbury

Minnesota Oncology - Woodbury

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Missouri
Bonne Terre

Parkland Health Center-Bonne Terre

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Cape Girardeau

Saint Francis Medical Center

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Southeast Cancer Center

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Columbia

Ellis Fischel Cancer Center at University of Missouri - Columbia

Donald C Doll
Ph: 573-882-7440

Independence

Independence Regional Health Center

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Jefferson City

Goldschmidt Cancer Center

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Kansas City

Heartland Hematology Oncology Associates, Incorporated

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Research Medical Center

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Saint Luke's Hospital

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Lee's Summit

Saint Luke's East - Lee's Summit

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Liberty

Parvin Radiation Oncology

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Saint Joseph

Heartland Regional Medical Center

Rakesh Gaur
Ph: 913-948-5588
Email: aroland@kccop.org

Saint Louis

David C. Pratt Cancer Center at St. John's Mercy

Jay W Carlson
Ph: 800-821-7532

Mercy Clinic St. Louis Cancer and Breast Institute

Jay W Carlson
Ph: 800-821-7532

Missouri Baptist Cancer Center

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis

Nancy L. Bartlett
Ph: 800-600-3606
Email: info@siteman.wustl.edu

Springfield

Hulston Cancer Center at Cox Medical Center South

Jay W Carlson
Ph: 800-821-7532

St. John's Regional Health Center

Jay W Carlson
Ph: 800-821-7532

Sullivan

Missouri Baptist Sullivan Hospital

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Sunset Hills

Missouri Baptist Outpatient Center-Sunset Hills

James L. Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

Montana
Billings

Billings Clinic Cancer Center - 801 N 29th Street

Benjamin Thomas Marchello
Ph: 800-648-6274

CCOP - Montana Cancer Consortium

Benjamin Thomas Marchello
Ph: 800-648-6274

St. Vincent Healthcare Cancer Care Services

Benjamin Thomas Marchello
Ph: 800-648-6274

Bozeman

Bozeman Deaconess Cancer Center

Benjamin Thomas Marchello
Ph: 800-648-6274

Butte

St. James Healthcare Cancer Care

Benjamin Thomas Marchello
Ph: 800-648-6274

Great Falls

Benefis Sletten Cancer Institute

Benjamin Thomas Marchello
Ph: 800-648-6274

Helena

St. Peter's Hospital

Benjamin Thomas Marchello
Ph: 800-648-6274

Kalispell

Kalispell Regional Medical Center

Benjamin Thomas Marchello
Ph: 800-648-6274

Missoula

Community Medical Center

Benjamin Thomas Marchello
Ph: 800-648-6274

Montana Cancer Center at St. Patrick Hospital and Health Sciences Center

Benjamin Thomas Marchello
Ph: 800-648-6274

New Hampshire
Lebanon

Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center

Frederick Lansigan
Ph: 800-639-6918
Email: cancer.research.nurse@dartmouth.edu

Nashua

Norris Cotton Cancer Center Nashua

Frederick Lansigan
Ph: 800-639-6918
Email: cancer.research.nurse@dartmouth.edu

New Jersey
East Orange

Veterans Affairs Medical Center - East Orange

Victor T Chang
Ph: 800-475-2336
Email: patricia.goyer@med.va.gov

New York
Bronx

Jack D. Weiler Hospital at Montefiore Medical Center - East Campus

Ramakrishna Battini
Ph: 718-904-2730
Email: aecc@aecom.yu.edu

Montefiore Medical Center

Ramakrishna Battini
Ph: 718-904-2730
Email: aecc@aecom.yu.edu

Glens Falls

Charles R. Wood Cancer Center at Glens Falls Hospital

John P Stoutenburg
Ph: 518-926-6700

New York

Mount Sinai Medical Center

Samir Sunil Parekh
Ph: 212-824-7320
Email: jenny.figueroa@mssm.edu

New York Weill Cornell Cancer Center at Cornell University

Peter Martin
Ph: 212-746-1848

Rochester

James P. Wilmot Cancer Center at University of Rochester Medical Center

Jonathan W Friedberg
Ph: 585-275-5830

North Carolina
Clinton

Southeastern Medical Oncology Center-Clinton

James N. Atkins
Ph: 919-580-0000

Goldsboro

Southeastern Medical Oncology Center - Goldsboro

James N. Atkins
Ph: 919-580-0000

Wayne Memorial Hospital, Incorporated

James N. Atkins
Ph: 919-580-0000

Hendersonville

Comprehensive Cancer Center at Pardee Hospital

James E. Radford
Ph: 828-696-4716

Hendersonville Hematology and Oncology

James E. Radford
Ph: 828-696-4716

Jacksonville

Southeastern Medical Oncology Center-Jacksonville

James N. Atkins
Ph: 919-580-0000

Kinston

Kinston Medical Specialists

Peter R. Watson
Ph: 252-559-2200

Statesville

Iredell Memorial Hospital

Ruby A. Grimm
Ph: 704-873-5661

Wilson

Southeastern Medical Oncology Center - Wilson

James N. Atkins
Ph: 919-580-0000

Winston-Salem

Wake Forest University Comprehensive Cancer Center

Zanetta S Lamar
Ph: 336-713-6771

Ohio
Akron

Summa Center for Cancer Care at Akron City Hospital

Jennifer E Payne
Ph: 330-375-6101

Barberton

Barberton Citizens Hospital

Jennifer E Payne
Ph: 330-375-6101

Beachwood

Cleveland Clinic Taussig Cancer Center

Anjali S Advani
Ph: 866-223-8100

Cincinnati

Oncology Hematology Care Inc - Western Hills

Howard M. Gross
Ph: 937-775-1350

Oncology Hematology Care, Incorporated - Anderson

Howard M. Gross
Ph: 937-775-1350

Oncology Hematology Care, Incorporated - Blue Ash

Howard M. Gross
Ph: 937-775-1350

Oncology Hematology Care, Incorporated - Kenwood

Howard M. Gross
Ph: 937-775-1350

Oncology Hematology Care, Incorporated - Mt. Auburn/Taft Road

Howard M. Gross
Ph: 937-775-1350

University of Cincinnati

Stephen C Medlin
Ph: 513-558-4553
Email: uchealthnews@uc.edu

Cleveland

Case Comprehensive Cancer Center

Paolo F Caimi
Ph: 800-641-2422

Cleveland Clinic Cancer Center at Fairview Hospital

Anjali S Advani
Ph: 866-223-8100

Cleveland Clinic Taussig Cancer Center

Anjali S Advani
Ph: 866-223-8100

MetroHealth Cancer Care Center at MetroHealth Medical Center

Bruce J. Averbook
Ph: 216-778-8526
Email: kbauchens@metrohealth.org

Columbus

Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center

Kristie A. Blum
Ph: 800-293-5066
Email: Jamesline@osumc.edu

Dayton

David L. Rike Cancer Center at Miami Valley Hospital

Howard M. Gross
Ph: 937-775-1350

Good Samaritan Hospital

Howard M. Gross
Ph: 937-775-1350

Samaritan North Cancer Care Center

Howard M. Gross
Ph: 937-775-1350

Elyria

Mercy Cancer Center - Elyria

Paolo F Caimi
Ph: 800-641-2422

Fairfield

Oncology Hematology Care, Incorporated - Fairfield Healthplex

Howard M. Gross
Ph: 937-775-1350

Findlay

Blanchard Valley Regional Cancer Center

Howard M. Gross
Ph: 937-775-1350

Franklin

Atrium Medical Center

Howard M. Gross
Ph: 937-775-1350

Greenville

Wayne Hospital

Howard M. Gross
Ph: 937-775-1350

Independence

Cleveland Clinic Taussig Cancer Center

Anjali S Advani
Ph: 866-223-8100

Kettering

Charles F. Kettering Memorial Hospital

Howard M. Gross
Ph: 937-775-1350

Mansfield

Cleveland Clinic Cancer Center Mansfield

Anjali S Advani
Ph: 866-223-8100

Mayfield Heights

Hillcrest Cancer Center at Hillcrest Hospital

Anjali S Advani
Ph: 866-223-8100

Mentor

Lake/University Ireland Cancer Center

Paolo F Caimi
Ph: 800-641-2422

Sandusky

North Coast Cancer Care, Incorporated

Anjali S Advani
Ph: 866-223-8100

Strongsville

Cleveland Clinic Foundation - Strongsville

Anjali S Advani
Ph: 866-223-8100

Troy

UVMC Cancer Care Center at Upper Valley Medical Center

Howard M. Gross
Ph: 937-775-1350

Warrensville Heights

South Pointe Hospital Cancer Care Center

Anjali S Advani
Ph: 866-223-8100

West Chester

University Pointe

Stephen C Medlin
Ph: 513-558-4553
Email: uchealthnews@uc.edu

Westlake

UH-Seidman Cancer Center at Saint John Medical Center

Paolo F Caimi
Ph: 800-641-2422

Wooster

Cleveland Clinic - Wooster

Anjali S Advani
Ph: 866-223-8100

Oklahoma
Oklahoma City

Stephenson Cancer Center at the University of Oklahoma

Mohamad Cherry
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Tulsa

Cancer Care Associates-Yale

Mohamad Cherry
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Oregon
Clackamas

Clackamas Radiation Oncology Center

Alison K Conlin
Ph: 503-215-6412

Newberg

Providence Newberg Medical Center

Alison K Conlin
Ph: 503-215-6412

Oregon City

Willamette Falls Hospital

Alison K Conlin
Ph: 503-215-6412

Portland

Providence Cancer Center at Providence Portland Medical Center

Alison K Conlin
Ph: 503-215-6412

Providence St. Vincent Medical Center

Alison K Conlin
Ph: 503-215-6412

Pennsylvania
Danville

Geisinger Cancer Institute at Geisinger Health

Edward J Gorak
Ph: 570-271-5251

Hazleton

Geisinger Hazleton Cancer Center

Edward J Gorak
Ph: 570-271-5251

Lewisburg

Geisinger Medical Oncology at Evangelical Community Hospital

Edward J Gorak
Ph: 570-271-5251

Lewistown

Lewistown Hospital

Edward J Gorak
Ph: 570-271-5251

Philadelphia

Fox Chase Cancer Center - Philadelphia

Michael M Millenson
Ph: 215-728-4790

Pottstown

Pottstown Memorial Regional Cancer Center

Wei Song
Ph: 610-327-7544

Pottsville

Geisinger Medical Oncology-Pottsville

Edward J Gorak
Ph: 570-271-5251

State College

Geisinger Medical Group - Scenery Park

Edward J Gorak
Ph: 570-271-5251

Mount Nittany Medical Center

John P Ford
Ph: 814-231-7813
Email: smoyer@mountnittany.org

West Reading

McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center

Terrence P. Cescon
Ph: 610-988-9323

Wilkes-Barre

Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center

Edward J Gorak
Ph: 570-271-5251

South Carolina
Spartanburg

Gibbs Regional Cancer Center at Spartanburg Regional Medical Center

Charles E Bowers
Ph: 800-486-5941

Tennessee
Kingsport

Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center

Asheesh Shipstone
Ph: 423-578-8538

Kingsport Hematology-Oncology Associates

Asheesh Shipstone
Ph: 423-578-8538

Texas
Dallas

Parkland Memorial Hospital

Harris V Naina
Ph: 214-648-7097

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas

Harris V Naina
Ph: 214-648-7097

Virginia
Charlottesville

University of Virginia Cancer Center

Michael Eugene Williams
Ph: 434-243-6143

Martinsville

Ravenel Oncology Center at Memorial Hospital of Martinsville and Henry County

Sreedhar Katragadda
Ph: 276-666-7827

Washington
Kennewick

Columbia Basin Hematology

Brian G Till
Ph: 800-422-6237

Kirkland

Cascade Cancer Center at Evergreen Hospital Medical Center

Brian G Till
Ph: 800-422-6237

Brian G Till
Ph: 800-422-6237

Longview

Lower Columbia Regional Cancer Center at PeaceHealth-St. John Medical Center

Alison K Conlin
Ph: 503-215-6412

Mount Vernon

Skagit Valley Hospital Cancer Care Center

Brian G Till
Ph: 800-422-6237

Brian G Till
Ph: 800-422-6237

Port Angeles

Olympic Medical Center

Brian G Till
Ph: 800-422-6237

Seattle

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Brian G Till
Ph: 800-422-6237

Seattle Cancer Care Alliance

Brian G Till
Ph: 800-422-6237

University Cancer Center at University of Washington Medical Center

Brian G Till
Ph: 800-422-6237

Sequim

Olympic Medical Cancer Center

Brian G Till
Ph: 800-422-6237

Spokane

Cancer Care Northwest - North

Brian G Till
Ph: 800-422-6237

Cancer Care Northwest - Spokane South

Brian G Till
Ph: 800-422-6237

Cancer Care Northwest - Valley

Brian G Till
Ph: 800-422-6237

Vancouver

Southwest Washington Medical Center Cancer Center

Alison K Conlin
Ph: 503-215-6412

Wenatchee

Confluence Health - Wenatchee Valley Medical Center

Brian G Till
Ph: 800-422-6237

West Virginia
Morgantown

Mary Babb Randolph Cancer Center at West Virginia University Hospitals

Abraham S Kanate
Ph: 304-293-2745
Email: sfilburn@hsc.wvu.edu

Wisconsin
Antigo

Langlade Memorial Hospital

Hamied R. Rezazadeh
Ph: 877-405-6866

Fond Du Lac

Central Wisconsin Cancer Program at Agnesian HealthCare

Michael W Jones
Ph: 800-494-2927

Green Bay

Green Bay Oncology, Limited at St. Mary's Hospital

Brian L Burnette
Ph: 800-432-6049

Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center

Brian L Burnette
Ph: 800-432-6049

St. Mary's Hospital Medical Center - Green Bay

Brian L Burnette
Ph: 800-432-6049

St. Vincent Hospital Regional Cancer Center

Brian L Burnette
Ph: 800-432-6049

La Crosse

Gundersen Lutheran Center for Cancer and Blood

Kurt Oettel
Ph: 608-775-2385
Email: cancerctr@gundluth.org

Manitowoc

Holy Family Memorial Medical Center Cancer Care Center

Brian L Burnette
Ph: 800-432-6049

Marinette

Bay Area Cancer Care Center at Bay Area Medical Center

Brian L Burnette
Ph: 800-432-6049

Milwaukee

Froedtert Hospital and Medical College of Wisconsin

Timothy S Fenske
Ph: 414-805-4380

Mukwonago

D.N. Greenwald Center

Timothy R Wassenaar
Ph: 262-928-7878

New Richmond

Cancer Center of Western Wisconsin

Joseph W Leach
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Oconomowoc

Regional Cancer Center at Oconomowoc Memorial Hospital

Timothy R Wassenaar
Ph: 262-928-7878

Oconto Falls

Green Bay Oncology, Limited - Oconto Falls

Brian L Burnette
Ph: 800-432-6049

Sheboygan

Saint Nicholas Hospital

Brian L Burnette
Ph: 800-432-6049

Sturgeon Bay

Green Bay Oncology, Limited - Sturgeon Bay

Brian L Burnette
Ph: 800-432-6049

Waukesha

Waukesha Memorial Hospital Regional Cancer Center

Timothy R Wassenaar
Ph: 262-928-7878

Wausau

University of Wisconcin Cancer Center at Aspirus Wausau Hospital

Hamied R. Rezazadeh
Ph: 877-405-6866

Wyoming
Cody

Big Horn Basin Cancer Center

Benjamin Thomas Marchello
Ph: 800-648-6274

Billings Clinic-Cody

Benjamin Thomas Marchello
Ph: 800-648-6274

Sheridan

Welch Cancer Center at Sheridan Memorial Hospital

Benjamin Thomas Marchello
Ph: 800-648-6274

Canada

Saskatchewan
Regina

Allan Blair Cancer Centre at Pasqua Hospital

Haji I Chalchal
Ph: 306-766-2213

Saskatoon

Saskatoon Cancer Centre at the University of Saskatchewan

Waleed S Ismail
Ph: 306-655-2914

Link to the current ClinicalTrials.gov record.
NLM Identifier NCT01415752
ClinicalTrials.gov processed this data on April 09, 2015

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.